I

    Ionis Pharmaceuticals Inc (IONS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $60.36
    -0.69 (-1.13%)

    Market Cap: $10.15B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(31/40)
    Avg Surprise
    +65.89%
    Streak
    14 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.92
    Range$-1.06 - $-0.65
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.81+11.6%
    60d ago$-0.81+11.6%
    30d ago$-0.81+12.1%
    7d ago$-0.89+2.9%
    Current$-0.92
    Revenue Consensus
    $184M
    Range$152M - $225M
    19 analysts
    Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.42 - $0.45
    9 analysts
    Revenue Consensus
    $343M
    Range$212M - $417M
    23 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$-0.92---
    Jun 26
    		$-0.70$-1.09+35.78%Beat-182.4%
    Mar 26
    		$-0.30N/A+61.04%Beat+67.4%
    Dec 25
    		$-1.15$-1.33+13.68%Beat-166.8%
    Sep 25
    		$-0.61$-1.05+41.90%Beat+35.8%
    Jun 25
    		$0.85$0.16+431.25%Beat+454.2%
    Mar 25
    		$-0.92$-1.03+10.68%Beat-19.5%
    Dec 24
    		$-0.43$-0.84+49.03%Beat-617.3%
    Sep 24
    		$-0.95$-1.16+18.10%Beat-11.8%
    Jun 24
    		$-0.24N/A+68.42%Beat+41.5%
    Mar 24
    		$-0.77$-0.83+7.23%Beat-13.2%
    Dec 23
    		$-0.06N/A+92.77%Beat+95.6%
    Sep 23
    		$-0.85$-0.89+4.49%Beat-431.3%
    Jun 23
    		$-0.41$-0.70+41.43%Beat+26.8%
    Mar 23
    		$-0.68$-0.76+10.53%Beat-151.9%
    Dec 22
    		$-1.36$-0.92-47.83%Miss-196.5%
    Sep 22
    		$-0.16N/A+69.81%Beat+52.9%
    Jun 22
    		$-0.56$-0.47-19.15%Miss-115.4%
    Mar 22
    		$-0.27$-0.52+48.08%Beat+15.6%
    Dec 21
    		$1.41$0.28+403.57%Beat+220.5%
    Sep 21
    		$-0.34$-0.32-6.25%Miss-54.5%
    Jun 21
    		$-0.26$-0.32+18.75%Beat-13.0%
    Mar 21
    		$-0.32$-0.25-28.00%Miss+8.6%
    Dec 20
    		$0.44$0.28+57.14%Beat-68.8%
    Sep 20
    		$-0.22$-0.16-37.50%Miss-222.2%
    Jun 20
    		$-0.23$-0.28+17.86%Beat-2200.0%
    Mar 20
    		$-0.35$-0.11-218.18%Miss-156.5%
    Dec 19
    		$1.41$0.93+51.61%Beat+642.1%
    Sep 19
    		$0.18$-0.32+156.25%Beat+700.0%
    Jun 19
    		$-0.01N/A+95.00%Beat+96.6%
    Mar 19
    		$0.62$0.78-20.51%Miss+6300.0%
    Dec 18
    		$0.19$-0.05+480.00%Beat+850.0%
    Sep 18
    		$-0.03N/A+82.35%Beat-782.4%
    Jun 18
    		$-0.29$-0.19-52.63%Miss-222.2%
    Mar 18
    		$-0.01N/A+93.33%Beat-133.3%
    Dec 17
    		$0.02$0.01+100.00%Beat-91.7%
    Sep 17
    		$-0.00N/A+95.75%Beat-105.7%
    Jun 17
    		$-0.09$-0.06-50.00%Miss-
    Mar 17
    		$0.03N/A+109.68%Beat-
    Dec 16
    		$0.24$-0.12+300.00%Beat-
    Sep 16
    		$0.06$0.04+50.00%Beat-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio-21.88EV/EBITDA135.77x
    Price/FCF-17.80xFCF Yield-5.62%
    Profitability
    Profit Margin-64.70%Operating Margin-38.20%
    ROE-105.50%ROIC-34.60%
    Financial Health
    Debt/Equity3.01xInterest Coverage-6.81x
    Current Ratio7.89xQuick Ratio7.73x
    Trading Statistics
    Beta0.40Avg Volume2.26M
    52-Week High$86.7452-Week Low$49.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$61.17
    SMA 20$58.63
    SMA 50$62.62
    SMA 200$73.67
    EMA 10$60.75
    EMA 20$59.83
    EMA 50$62.16
    EMA 200$66.97

    MACD

    Line: 0.53Signal: -0.19Hist: 0.71

    ADX

    ADX: 20.3+DI: 26.4-DI: 25.9

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down16.0
    PSAR$64.11

    Bollinger Bands

    Upper Band$64.61
    Lower Band$52.66
    %B Position2038%(Upper)
    Band Width0.64

    RSI (14-Day)

    Neutral
    51.1

    Momentum Oscillators

    Stoch %K68.6
    Stoch %D79.0
    Williams %R-41.3
    ROC (10d)3.0%
    Momentum1.73
    CCI (20d)47.2
    MFI (14d)63.0

    Volatility Measures

    ATR (14d)$2.02(3.3%)
    StdDev (20d)2.99
    Hist Vol34.1%(Moderate)

    Volume Flow

    VWAP$60.33
    OBV67.1M
    AD Line35.4M
    CMF (20d)0.170

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.9x
    VWMA (20d)$58.68

    Pivot Points

    R3$63.05
    R2$62.37
    R1$61.71
    Pivot Point$61.03
    S1$60.37
    S2$59.69
    S3$59.03

    Advanced Oscillators

    TSI5.42
    Ultimate Osc59.3
    KST35.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$267.95M$246.09M$203.33M$156.72M$452.05M$131.61M$226.58M$133.81M$225.25M$119.50M$324.50M$144.21M
    Cost of Revenue$2.74M$2.98M$7.96M$2.34M$4.15M$1.46M$3.83M$1.07M$4.16M$2.15M$3.06M$2.19M
    Gross Profit$265.21M$243.11M$195.37M$154.38M$447.90M$130.15M$222.75M$132.74M$221.09M$117.35M$321.44M$142.02M
    Operating Expenses$367.50M$360.53M$409.83M$314.56M$308.08M$277.01M$333.57M$281.40M$287.18M$266.86M$327.56M$285.28M
    R&D$217.11M$210.17M$279.65M$217.75M$217.46M$200.76M$245.49M$219.76M$222.06M$214.22M$256.56M$215.33M
    SG&A$150.40M$150.36M$130.19M$96.81M$90.62M$76.25M$88.08M$61.64M$65.11M$52.64M$71.01M$69.95M
    Operating Income$-102,293,000$-117,424,000$-214,458,000$-160,182,000$139.82M$-146,860,000$-110,821,000$-148,656,000$-66,091,000$-149,513,000$-6,122,000$-143,265,000
    Interest Income$10.05M$48.07M$25.52M$53.59M$6.38M$22.50M$26.34M$27.11M$22.07M$28.62M$25.53M$21.99M
    Interest Expense$22.12M$22.50M$22.69M$22.16M$22.76M$22.93M$22.86M$22.69M$22.79M$22.11M$22.41M$21.98M
    Income Before Tax$-113,382,000$-92,310,000$-227,917,000$-128,393,000$123.53M$-146,822,000$-107,038,000$-144,101,000$-66,201,000$-142,728,000$-2,766,000$-140,808,000
    Income Tax Expense$1.26M$218,000$1.48M$213,000$-20,000$116,000$-2,689,000$-3,621,000$64,000$75,000$6.50M$6.60M
    Net Income$-114,646,000$-92,528,000$-229,394,000$-128,606,000$123.55M$-146,938,000$-104,349,000$-140,480,000$-66,265,000$-142,803,000$-9,263,000$-147,410,000
    EBITDA$-95,210,000$-114,274,000$-227,109,000$-158,750,000$141.15M$-146,464,000$-113,028,000$-150,483,000$-68,117,000$-151,175,000$-7,100,000$-141,442,000
    EBIT$-101,306,000$-117,880,000$-230,746,000$-159,819,000$139.92M$-146,395,000$-110,519,000$-148,514,000$-65,481,000$-149,236,000$-5,887,000$-140,818,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IONS

    News

    Canaccord reiterates Ionis Pharmaceuticals stock Buy rating at $95 By Investing.com

    Canaccord Genuity has reiterated its Buy rating and $95 price target for Ionis Pharmaceuticals following recent investor meetings. The firm highlighted Ionis's two approved products, Tryngolza and Dawnzera, and anticipates two potential product approvals in the coming months for Zilganersen and Bepirovirsen. Despite analysts not expecting profitability this year, Ionis reaffirmed its goal to achieve cash flow breakeven by 2028, with strong liquid assets.

    Investing.com Canada•8/24/26•
    Bullish

    FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia

    The FDA has expanded the label for Ionis Pharmaceuticals' drug, Tryngolza (olezarsen), to treat severe hypertriglyceridemia (sHTG), making it the first approved treatment for this condition in the U.S. This approval significantly broadens Tryngolza's market, as it was previously approved only for familial chylomicronemia syndrome (FCS). Ionis plans to launch the drug for sHTG next month, leveraging its first-mover advantage in a market affecting nearly 3 million people.

    Eastern Progress•8/23/26•
    Bullish

    Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

    Ionis Pharmaceuticals (IONS) reported a Q1 loss of $0.3 per share, significantly beating the Zacks Consensus Estimate of a $0.85 loss and improving from a $0.75 loss a year ago. The company also exceeded revenue expectations, posting $246 million against an estimate of $132 million. Despite this positive earnings surprise, Ionis Pharmaceuticals' shares have declined by 9.3% year-to-date, contrasting with the S&P 500's 4.3% gain.

    Eastern Progress•8/22/26•
    Neutral

    The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following New ESC 2026 RNA Data Package – Learn Why

    Ionis Pharmaceuticals will present new data for TRYNGOLZA, early-stage results for ION775, and Phase 3 eplontersen data at the ESC Congress 2026. This data package showcases Ionis’ broad RNA medicines platform in cardiometabolic and rare diseases, potentially reinforcing confidence in revenue guidance and long-term margin leverage. However, the company remains loss-making and reliant on partner economics, with its investment narrative dependent on multiple late-stage outcomes.

    Sahm•8/21/26•
    Somewhat-Bullish

    Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

    Ionis Pharmaceuticals will present new data on severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) Congress 2026. The presentations will include one-year data for TRYNGOLZA®, a recently approved treatment for sHTG, and Phase 1 data for ION775, an investigational siRNA. These presentations aim to highlight Ionis's continued leadership and commitment to advancing treatments for sHTG.

    Yahoo Finance•8/20/26•
    Bullish

    Frequently Asked Questions About IONS

    Does IONS pay dividends?
    Ionis Pharmaceuticals Inc (IONS) has a dividend payment track record. See the IONS dividend history page for its current payment status, yield, and streaks.
    What is IONS's market cap?
    Ionis Pharmaceuticals Inc (IONS) has a market capitalization of $10.15B with a current stock price of $60.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In